Full Text View
Tabular View
No Study Results Posted
Related Studies
ERP N1 as a Treatment Predictor of Generalized Anxiety Disorder
This study is currently recruiting participants.
Study NCT00613067   Information provided by Inje University
First Received: January 29, 2008   Last Updated: August 5, 2009   History of Changes

January 29, 2008
August 5, 2009
December 2007
September 2009   (final data collection date for primary outcome measure)
Event related potential (ERP) N100 [ Time Frame: Baseline ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00613067 on ClinicalTrials.gov Archive Site
- HAMA - HAMD - CGI - Beck Anxiety Inventory(self rating) [ Time Frame: baseline, 2, 4, 8 weeks ] [ Designated as safety issue: No ]
Same as current
 
ERP N1 as a Treatment Predictor of Generalized Anxiety Disorder
The Amplitude Change of the Auditory Evoked N1 Component as a Predictor of Response to Escitalopram Treatment in Patients With Generalized Anxiety Disorder

Amplitude changes of the N1 and the N1/P2 ERP component in response to different tone intensities have been suggested as a correlative of central serotonergic activity. A strong loudness dependence amplitude increase (strong intensity dependence) reflects low serotonergic neurotransmission and vice versa. Many researchers assumed that the brain serotonergic activity could influence treatment response of highly selective serotonin reuptake inhibitors in depression and anxiety disorders. There are a couple of studies reporting associations of N1 amplitude intensity dependence with response to Citalopram (positive correlation) and Reboxetine (negative correlation) treatment in major depressive disorder patients. But so far there have been no reports about associations between ERP N1 and antidepressant response in GAD patients.

So, it would be very interesting to explore the correlations between ERP N1 amplitude change and the Escitalopram treatment responsiveness in GAD patients.

 
 
Interventional
Treatment, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study
Generalized Anxiety Disorder
Drug: escitalopram
Experimental: 35 patients with Generalized Anxiety disorder

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Recruiting
35
September 2009
September 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • DSM-IV TR for GAD
  • Hamilton Rating Scale for Anxiety (HAMA) >18
  • 18 to 65 years old

Exclusion Criteria:

  • Severe medical illness
  • Other psychiatric illness
  • HAMD > 18
  • High suicidal risk
  • pregnancy
Both
18 Years to 65 Years
No
Contact: Jeong In Kim, Master 82-31-910-7260 p5p52@hanmail.net
Korea, Republic of
 
NCT00613067
Seung-Hwan Lee, Department of Psychiatry, Inje Univ. Ilsanpaik Hospital
IB-0709-053
Inje University
 
Principal Investigator: Seung-Hwan Lee, MD, PhD Psychiatry department, Inje Univ. Ilsanpaik Hospital
Study Director: Young-Min Park, MD, PhD Psychiatry department, Inje Univ. Ilsanpaik Hospital
Study Director: Sung-Man Bae, PhD Psychiatry department, Inje Univ. Ilsanpaik Hospital
Inje University
August 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP